Results 201 to 207 of about 11,256 (207)

Discovery of Novel 4-Hydroxyquinazoline Derivatives: In Silico, in Vivo and in Vitro Studies Using Primary PARPi-Resistant Cell Lines

Molecules
Dingding Gao, Guangzhao Xu
exaly  

Fuzuloparib With or Without Apatinib as Maintenance Therapy in Newly Diagnosed, Advanced Ovarian Cancer (FZOCUS-1): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

Ca-A Cancer Journal for Clinicians
Jianqing Zhu, Ning Li, WenJun Cheng
exaly  

CA-125 KELIM as an Alternative Predictive Tool to Identify Which Patients Can Benefit From PARPi in High-Grade Serous Advanced Ovarian Cancer: A Retrospective Pilot Diagnostic Accuracy Study

International Journal of Molecular Sciences
Panagiotis Tzitzis, Kimon Chatzistamatiou, Grigoris F Grimbizis   +2 more
exaly  

Poly (ADP-Ribose) Polymerase Inhibitors (PARPi) Therapy Response in an Acral Melanoma Patient With EMSY Gene Amplification

JAAD Case Reports
Alice Y Zhou, George Ansstas, Omar H Butt   +2 more
exaly  

Targeted Therapies and PARPi Therapy Response Following ICI Therapy Failure in Advanced Melanoma: A Case Series

Melanoma Management
George Ansstas, Jordan Phillipps, George Nassief   +2 more
exaly  

CHK1 (SRA737)/PARPI COMBINATION METHODS OF INHIBITING TUMOR GROWTH

2018
HASSIG CHRISTIAN, STROUSE BRYAN, HANSEN RYAN, ANDERES KENNA   +3 more
openaire   +3 more sources

[Landscape and challenges of PARPi in the treatment of epithelial ovarian carcinoma].

Zhonghua fu chan ke za zhi
N, Li, L Y, Wu
openaire   +1 more source